Segall Bryant & Hamill LLC Trims Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Segall Bryant & Hamill LLC trimmed its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 3.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 112,617 shares of the company’s stock after selling 4,599 shares during the quarter. Segall Bryant & Hamill LLC owned 0.34% of TransMedics Group worth $17,681,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue acquired a new position in shares of TransMedics Group during the third quarter valued at approximately $2,560,000. Vaughan Nelson Investment Management L.P. raised its position in TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares during the period. WCM Investment Management LLC acquired a new position in TransMedics Group in the 3rd quarter valued at about $8,720,000. Allspring Global Investments Holdings LLC increased its stake in TransMedics Group by 5.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock worth $94,061,000 after buying an additional 30,092 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new position in TransMedics Group in the second quarter worth approximately $1,400,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $77.20 on Thursday. The company’s 50 day simple moving average is $123.41 and its two-hundred day simple moving average is $138.93. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a 1 year low of $66.76 and a 1 year high of $177.37. The stock has a market capitalization of $2.59 billion, a PE ratio of 82.13 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the prior year, the company earned ($0.12) earnings per share. TransMedics Group’s revenue was up 63.7% compared to the same quarter last year. Analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. This represents a 12.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares in the company, valued at $3,714,902.10. This trade represents a 32.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,958 shares of company stock valued at $5,230,528. Insiders own 7.00% of the company’s stock.

Analyst Ratings Changes

TMDX has been the subject of several analyst reports. Stephens increased their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Canaccord Genuity Group reduced their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday. Robert W. Baird cut their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. JPMorgan Chase & Co. dropped their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research note on Tuesday, October 29th. Finally, Piper Sandler reduced their price target on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $131.80.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.